Compare Amazon.com Inc (AMZN) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Amazon (AMZN) trades at $245.34, down 0.69% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings, beating expectations with EPS of $2.78, and shows robust revenue growth, reaching $716.92B in 2025. Operating cash flow remains strong at $139.51B, though heavy investing activities result in modest net cash flow. Analyst sentiment is overwhelmingly positive, with 88.3% recommending Buy and a consensus price target of $320.75.

The outlook for Amazon is favorable, driven by AI advancements in AWS and expanding market penetration. Key risks include intense competition in retail and cloud sectors, high capital expenditures, and macroeconomic pressures. Investors should weigh the strong growth trajectory against these risks, with the stock offering significant upside based on analyst targets.

DNA trades at $9.09, down 6.58% on the day, reflecting ongoing investor caution. The technical outlook is bullish based on moving averages, with key support at $9 and resistance at $10. Fundamentally, the company reported a net loss of $312.76M on $170.16M revenue in 2025, with a negative net margin of -201.05%. Recent news highlights include Ginkgo Bioworks' Q1 2026 results and its strategic pivot to autonomous laboratories following the divestiture of its biosecurity business.

The outlook remains challenging due to persistent losses and high cash burn, though the technical setup suggests potential for a near-term bounce. Investment opportunity hinges on successful execution of the new lab strategy driving future profitability. Key risks include continued negative earnings, competitive pressures in biotech, and reliance on the unproven autonomous lab model for growth.